MedPath

Comprehensive Lifestyle Improvement Program for Men With Prostate Cancer

Not Applicable
Completed
Conditions
Prostate Cancer
Interventions
Behavioral: CLIPP
Registration Number
NCT04000464
Lead Sponsor
University of Arizona
Brief Summary

This study is an investigator initiated clinical study. A prospective, single arm unblinded, open label study will be carried out to determine the feasibility of recruitment, retention and adherence of 30 prostate cancer survivors who have been on androgen deprivation therapy within the last 5 years for a lifestyle modification intervention.

Detailed Description

Introduction

* Androgen deprivation therapy (ADT) has been demonstrated to improve disease free and over-all survival in men with prostate cancer (PCa).

* ADT for PCa is associated with adverse cardio-metabolic effects such as reduced libido, hot flashes, metabolic syndrome, diabetes, myocardial infarction and stroke. This reduces quality of life (QoL) and potentially affects mortality.

* There is paucity of data regarding comprehensive lifestyle interventions in men on ADT for Pca. Existing studies used non-standardized interventions or lack data on metabolic risk factors.

* CLIPP is designed to address these gaps by using an intervention modelled after the Diabetes Prevention Program (DPP), a standardized multi-component intervention with demonstrated effectiveness in reducing diabetes risk factors that has been successfully adapted for multiple disease types including breast cancer.

Intervention:

* 24 Weeks

* Health Coaching Weekly

* Serum \& Urine Baseline, Week 12 and Week 24

* Anthropometric Measures

* Questionnaires

* Dual-energy X-ray absorptiometry (DXA) at Baseline and Week 24

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
31
Inclusion Criteria
  • Diagnosed with prostate cancer Stage I, II or IV
  • On androgen deprivation therapy with last 5 years
  • Willing to participate in a lifestyle modification program
  • Willing to modify diet and eating practices
  • Willing to participate in blood collection, urine collection and measurements
  • Minimum of 30 days since participating in another study/trial
  • English speaking
  • 40 years of age or older
Exclusion Criteria
  • Currently participating in another study or trial
  • Currently in hospice
  • Inability to walk two city blocks
  • Inability to comprehend informed consent or procedural requirements
  • Digestive Diseases (IBD, Diverticulitis, etc) that might prevent him from increasing fruit and vegetable intake

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Single ArmCLIPP24 Week Lifestyle Modification intervention
Primary Outcome Measures
NameTimeMethod
Reach Recruiting Target6 Months

Recruit 30 men with prostate cancer who have been on androgen deprivation therapy within the last 5 years.

Retention of Participants6 months

80% retention rate, or 24 out of 30 participants

Adherence to Intervention6 months

75% attendance rate throughout 24 intervention visits

Secondary Outcome Measures
NameTimeMethod
Hemoglobin A1c6 Months

Unit of Measure %

Lipid Panel6 Months

Unit of Measure Mg/dL

Specific Quality of Life Questionnaire6 Months

Expanded Prostate Cancer Index Composite Short Form (EPIC-26) - Scale of Measurement 0 to 4. 0=No Problem 1=Very Small problem 2=Small Problem 3=Moderate problem 4=Big Problem

Global Quality of Life Questionnaire6 Months

PROMIS Scale v 1.2 Global Health. Scale Measurements 1 to 5. 1=Poor 2=Fair 3=Good 4=Very Good 5= Excellent

Fasting Glucose6 Months

Unit of Measure Mg/dL

Trial Locations

Locations (1)

University of Arizona School of Medicine Collaboratory

🇺🇸

Tucson, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath